Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 149 participants.

Also called NCT01356849

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 149 participants (enrolled count) (from the registry)
Sponsor
AbbVie (prior sponsor, Abbott) (from the registry)
Registry
  • NCT NCT01356849
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Canada, Puerto Rico, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01356849. Randomized; quadruple masking; primary purpose treatment. Start 2011-04 (registry gives no type); primary completion 2012-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor
Acronym
RADAR
Condition
Diabetic Nephropathy
Intervention (Drug)
Atrasentan
Intervention (Drug)
Placebo
Lead sponsor
AbbVie (prior sponsor, Abbott) (class: industry)

Record details

Record id
cardio:ct-nct01356849
Content hash
f45da3301c5611ef0f98b3276f15288aafe7337127a689be08e657847d248eba